Literature DB >> 15757054

A comparison of continuous renal replacement therapy to intermittent dialysis in the management of renal insufficiency in the acutely III surgical patient.

Jimmy Waldrop1, David L Ciraulo, Timothy P Milner, Douglas Gregori, Aaron S Kendrick, Charles M Richart, Robert A Maxwell, Donald E Barker.   

Abstract

Acute renal failure (ARF) occurs in 10 per cent to 23 per cent of intensive care unit patients with mortality ranging from 50 per cent to 90 per cent. ARF is characterized by an acute decline in renal function as measured by urine output (UOP), serum creatinine, and blood urea nitrogen (BUN). Causes may be prerenal, intrarenal, or postrenal. Treatment consists of renal replacement therapy (RRT), either intermittent (ID) or continuous (CRRT). Indications for initiation of dialysis include oliguria, acidemia, azotemia, hyperkalemia, uremic complications, or significant edema. Overall, the literature comparing CRRT to ID is poor. No studies of only surgical/trauma patients have been published. We hypothesize that renal function and hemodynamic stability in trauma/ surgical critical care patients are better preserved by CRRT than by ID. We performed a retrospective review of trauma/surgical critical care patients requiring renal supportive therapy. Thirty patients received CRRT and 27 patients received ID. The study was controlled for severity of illness and demographics. Outcomes assessed were survival, renal function, acid-base balance, hemodynamic stability, and oxygenation/ventilation parameters. Populations were similar across demographics and severity of illness. Renal function, measured by creatinine clearance, was statistically greater with CRRT (P = 0.035). There was better control of azotemia with CRRT: BUN was lower (P = 0.000) and creatinine was lower (P = 0.000). Mean arterial blood pressure was greater (P = 0.021) with CRRT. No difference in oxygenation/ventilation parameters or pH was found between groups. CRRT results in an enhancement of renal function with improved creatinine clearance at the time of dialysis discontinuation. CRRT provides better control of azotemia while preserving hemodynamic stability in patients undergoing renal replacement therapy. Prospective randomized controlled studies and larger sample sizes are needed to further evaluate these modalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757054

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  6 in total

Review 1.  Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis.

Authors:  Antoine G Schneider; Rinaldo Bellomo; Sean M Bagshaw; Neil J Glassford; Serigne Lo; Min Jun; Alan Cass; Martin Gallagher
Journal:  Intensive Care Med       Date:  2013-02-27       Impact factor: 17.440

2.  Modality of RRT and Recovery of Kidney Function after AKI in Patients Surviving to Hospital Discharge.

Authors:  Kelly V Liang; Florentina E Sileanu; Gilles Clermont; Raghavan Murugan; Francis Pike; Paul M Palevsky; John A Kellum
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-17       Impact factor: 8.237

Review 3.  Acute renal failure and the critically ill surgical patient.

Authors:  Eliot Sykes; Joseph F Cosgrove
Journal:  Ann R Coll Surg Engl       Date:  2007-01       Impact factor: 1.891

Review 4.  Acute kidney injury in the elderly population.

Authors:  Rahmi Yilmaz; Yunus Erdem
Journal:  Int Urol Nephrol       Date:  2009-08-26       Impact factor: 2.370

5.  Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury.

Authors:  Monique M Elseviers; Robert L Lins; Patricia Van der Niepen; Eric Hoste; Manu L Malbrain; Pierre Damas; Jacques Devriendt
Journal:  Crit Care       Date:  2010-12-01       Impact factor: 9.097

6.  Use of Renal Replacement Therapy in a Neonatal Foal with Postresuscitation Acute Renal Failure.

Authors:  D M Wong; R E Ruby; A Eatroff; M J Yaeger
Journal:  J Vet Intern Med       Date:  2017-02-12       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.